On March 28, Alliance for Aging Research Vice President of Public Policy Cynthia Bens testified before the United States House of Representatives' Energy and Commerce Committee, Subcommittee on Health, at its hearing on the FDA’s Medical Device User Fee Program.
The Alliance for Aging Research submitted comments to the Centers for Medicare and Medicaid Services (CMS) on its proposal rule: CMS-3295-P, Medicare and Medicaid Programs; Hospital and Critical Access Hospital (CAH) Changes to Promote Innovation, Flexibility, and Improvement in Patient Care.
Letter to the House and Senate Appropriations Subcommittees on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies urging the Subcommittee to prioritize the U.S. Food and Drug Administration's (FDA) during Fiscal Year (FY) 2017 by increasing the agency's appropriated funding by $120 million.
Letter from the Alliance for Aging Research applauding the Senate Health, Education, Labor, and Pensions Committee's efforts in addressing the ways in which combination products are reviewed by the U.S. Food and Drug Administration (FDA).
This is a statement presented by Alliance Vice President of Public Policy Cynthia Bens at the December 18, 2015, stakeholder meeting regarding reauthorization of the Medical Device User Fee Act (MDUFA).
This is a statement presented by Alliance Vice President of Public Policy Cynthia Bens at the December 17, 2015, stakeholder meeting regarding reauthorization of the Prescription Drug User Fee Act (PDUFA).
This letter from various organizations, including the Alliance for Aging Research, to Rep. Harold Rogers, Rep. Tom Cole, Rep. Nita Lowey, and Rep. Rosa DeLauro requests "to restore the Fiscal Year (FY) 2016 302(b) allocation for the Labor, HHS, Education and Related Agencies Appropriations Subcommittee to at least the FY 2010 level of $163.6 billion."
This letter was from various organizations, including the Alliance for Aging Research, to Sen. Orrin Hatch and Sen. Michael Bennet to "express support for S. 185, the Promise for Antibiotics and Therapeutics for Health (PATH) Act, legislation to establish a new limited population antibacterial drug approval pathway for antibiotics to treat serious or life-threatening infections for which there exists an unmet medical need."
On October 23, 2014, the Alliance for Aging Research, with support from Mars, Inc., convened key stakeholders from the Institute of Medicine (IOM) and other non-profit organizations, the U.S. and Canadian Governments, academia, and private industry to discuss scientific evaluation of bioactive compounds. Dr. Joanne Lupton, Distinguished Professor of Nutrition at Texas A&M University, co-chaired the meeting with Susan Peschin, President and CEO of the Alliance for Aging Research, and described the goals of the meeting as follows: (1) to identify concrete ideas for creating an evaluation process for bioactives, including intake recommendations, and (2) to address issues with and opportunities for public-private partnerships. She also shared a working definition of bioactive compounds and suggested it be used for the discussion: Bioactives, according to the working definition, are “constituents in foods or dietary supplements, other than those needed to meet basic human needs, which are responsible for changes in health status.”
The meeting included four presentations that helped frame the discussion. These presentations were on perspectives from the Subcommittee on Dietary Reference Intakes (DRIs), application of the DRI paradigm to bioactives, lessons learned from research on cocoa flavanols, and development of public-private partnerships.
Download the full meeting summary to learn more.